Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Vifor Pharma AG
  6. Summary
    VIFN   CH0364749348

VIFOR PHARMA AG

(VIFN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
161.9(c) 161.9(c) 162(c) 161.9(c) 161.1(c) Last
145 705 470 367 411 302 362 797 376 576 Volume
+0.47% 0.00% +0.06% -0.06% -0.49% Change
More quotes
Estimated financial data (e)
Sales 2021 1 821 M 1 996 M 1 996 M
Net income 2021 265 M 290 M 290 M
Net cash position 2021 395 M 433 M 433 M
P/E ratio 2021 42,4x
Yield 2021 1,35%
Sales 2022 2 024 M 2 219 M 2 219 M
Net income 2022 308 M 337 M 337 M
Net cash position 2022 573 M 628 M 628 M
P/E ratio 2022 35,6x
Yield 2022 1,48%
Capitalization 10 448 M 11 453 M 11 452 M
EV / Sales 2021 5,52x
EV / Sales 2022 4,88x
Nbr of Employees 2 384
Free-Float -
More Financials
Company
Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject... 
Sector
Pharmaceuticals
Calendar
02/23Earnings Release
More about the company
Ratings of Vifor Pharma AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VIFOR PHARMA AG
01/20ChemoCentryx Announces EU Approval of TAVNEOS (avacopan) for the Treatment of ANCA-Asso..
AQ
01/19VFMCRP receives EU approval for Tavneos« for the treatment of ANCA-associated vasculiti..
BU
01/18VIFOR PHARMA : Fairness Opinion Vifor Pharma
PU
01/18CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held ..
BU
2021Vifor Pharma's Veltassa Cuts Serum Potassium Levels in Heart Failure Patients in Late-S..
MT
2021Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa«
BU
2021Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa«
CI
2021Cara Therapeutics' Korsuva Injection Receives TDAPA Reimbursement
MT
2021Vifor Pharma and American Regent announce settlement of Injectafer« patent litigation
BU
2021Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing ..
CI
2021Vifor Pharma to Sell Finished Drug Product Manufacturing Business to CordenPharma
MT
2021CSL, energy stocks drag Australia shares lower; tech rally limits losses
RE
2021Vifor Pharma drives transformation with divestment of non-core finished drug manufactur..
BU
2021CSL Closes $4.5 Billion Share Placement; to Open Share Purchase Plan; Shares Sink 8%
MT
2021CSL drags Australian shares lower, tech stocks rise
RE
More news
News in other languages on VIFOR PHARMA AG
01/21AKTIEN SCHWEIZ SCHLUSS : Talfahrt zum Wochenende noch beschleunigt
01/19VIFOR : feu vert européen pour Tavneos contre des vasculites
01/19Vifor-JV VFMCRP erhält EU-Zulassung für Tavneos bei Autoimmunerkrankungen
01/18Résumé des principales informations économiques du mardi 18 janvier
01/18VIFOR PHARMA : Fairness Opinion Vifor Pharma
More news
Analyst Recommendations on VIFOR PHARMA AG
More recommendations
Chart VIFOR PHARMA AG
Duration : Period :
Vifor Pharma AG Technical Analysis Chart | VIFN | CH0364749348 | MarketScreener
Technical analysis trends VIFOR PHARMA AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 161,10 CHF
Average target price 152,00 CHF
Spread / Average Target -5,65%
EPS Revisions
Managers and Directors
Shah Abbas Hussain Chief Executive Officer
Jacques Theurillat Chairman
Klaus Henning Jensen Chief Medical Officer
Michel Burnier Independent Director
Romeo Cerutti Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
VIFOR PHARMA AG-0.71%11 453
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356